Program overview
Context
Indication: Carcinoma, Non-Small-Cell Lung
Mechanism: Unknown
Modality: Unknown
Sponsor: Merck Sharp & Dohme
Low Signal
Raludotatug Deruxtecan
Raludotatug Deruxtecan is flagged as low signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 0/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 1/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT06780085 | https://clinicaltrials.gov/study/NCT06843447
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT06780085 | Low Signal (RECRUITING) | None | Low Signal | strict_eligibility_signal |
| NCT06843447 | Low Signal (RECRUITING) | None | Low Signal | large_enrollment_target_signal | strict_eligibility_signal |